Related Experiment Video

Updated: May 5, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

9.8K

Discussion of PARP inhibitors in cancer therapy

Monica Wielgos1, Eddy S Yang

  • 1Department of Radiation Oncology, Comprehensive Cancer Center, School of Medicine, University of Alabama at Birmingham, 1700 6th Avenue South, AL 35294-6832, USA.

Pharmaceutical Patent Analyst
|November 19, 2013
PubMed

Insights

Poly (ADP-ribose) polymerases (PARP) inhibitors show promise in cancer therapy by targeting DNA repair defects. Recent patents reveal novel strategies, including combinations with DNA-damaging agents, for improved cancer treatment outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerases (PARP) are crucial enzymes for maintaining genome integrity.
  • PARP inhibitors exploit synthetic lethality in homologous recombination repair-deficient tumors, enhancing therapeutic ratios.
  • Current research explores combining PARP inhibitors with DNA-damaging agents for sporadic cancer treatment.

Purpose of the Study:

  • To review recently patented PARP inhibitors and supporting literature.
  • To categorize patented compounds into single-agent or combination therapies.
  • To assess the potential impact of these agents on cancer therapy.

Main Methods:

  • Literature review of patented PARP inhibitors.
  • Categorization of patents based on therapeutic strategy (single-agent vs. combination).
  • Analysis of supporting scientific literature for patented claims.

Main Results:

  • Identification of patented PARP inhibitors for cancer treatment.
  • Classification of compounds into monotherapy and combination therapy patents.
  • Evidence supporting the efficacy of these agents in various cancer types.

Conclusions:

  • Patented PARP inhibitors represent a significant advancement in cancer therapy.
  • Combination strategies show potential for treating sporadic cancers.
  • Clinical trials will determine the impact of these agents on the therapeutic index in cancer treatment.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.7K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

3.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K